Long-Term Outcomes With Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks

This publication was sponsored by CSL Behring.

This article presents the results of an open-label extension of the COMPACT trial, wherein the long-term safety and efficacy of 40- and 60-IU/kg C1-INH(SC) were assessed, were reported in a 2019 publication by Craig et al. Only the 60 IU/kg dose of HAEGARDA is approved for use.

Download PDF